Update on P2F

RNS Number : 5456G
Remote Monitored Systems PLC
26 November 2020
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

26 November 2020

Remote Monitored Systems plc ("RMS" or the "Company")

Update on P2F

 

The Company is providing the following update on its wholly owned subsidiary Pharm 2 Farm Limited ("P2F").

 

As noted in the Company's announcement of 11 November 2020, the Directors have been expecting the delivery and installation of its new anti-viral mask production line at or around the end of November. Yesterday, 25 November 2020, the Company received an update from P2F and the manufacturer of the production line noting that the production machinery is now expected to undergo final acceptance testing in mid-December at the manufacturer's premises in Spain. It will then be shipped, installed and commissioned at P2F's Biocity premises in Nottingham. Commercial production and shipment of product is now expected to begin in January 2021. 

 

 

ENQUIRIES:

Remote Monitored Systems plc

Trevor Brown (Executive Director)                                                                +41 7941 55384

Paul Ryan (Non-Executive Chairman)    +32 475 754 148

 

SP Angel Corporate Finance LLP                                                                          +44 20 3470 0470

Nominated Adviser and joint broker            

Stuart Gledhill

Caroline Rowe

 

Peterhouse Capital Limited                                                                                  +44 20 7469 0930

Joint broker 

Lucy Williams

Duncan Vasey

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFEILTLEFII
UK 100

Latest directors dealings